This Week's Poll

At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you

Supported by Medilink UK

Barriers to adoption - Andrew Ives of - Advanced Therapeutic Materials - 9:13:48am Feb-10th

I see the main difficulty faced by any small company, be it start up or established SME, lies in the barriers which discourage adoption of new technologies within the NHS. Yes, a level of patient protection is needed, but many innovations fall foul of the full range of defenses even when there is little or no risk and great benefits. Despite a number of well sounding bodies and initiatives, I am yet to be convinced that a simple route exists through the labyrinth.

Agree/Disagree + add comment
Thumbs Up1 person agrees with this
 
 
t